Viewing data from:

AIRSUPRA

NDA

ALBUTEROL SULFATE; BUDESONIDE | N214070 | ASTRAZENECA PHARMACEUTICALS LP

1 strength1 unique patent2 unique exclusivities

Patent Timeline

1 unique patent, 2 exclusivities by expiration date

Active (1)TodayExclusivity

2026

2027

2028

2029

2030

Today

9415009

May. 28, 2030

Jan. 10, 2026

M-317

Sep. 15, 2028

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Airsupra (2023)

Total Spending

$925K

Total Claims

1,753

Beneficiaries

1,487

Avg Cost/Unit

$47.11

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Sep 18, 2025	SUPPL -1	View Letter (PDF)
Jan 11, 2023	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 0.09MG BASE/INH;0.08MG/INH

RLD

1 patent2 exclusivities▴

AEROSOL, METERED;INHALATION | Approved: Jan 10, 2023

Patents (1)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
9415009	May 28, 2030	—	—	—		—

Exclusivities (2)

Code	Date	Status
M-317	Sep 15, 2028	Active
NP	Jan 10, 2026	Expired